Kejiyao Pharmaceutical - B(02171)Included in the Southbound Hong Kong Stock Connect securities list

2026-03-09 02:37:29

Abstract generation in progress

Tongtong Finance APP News, CoGee Pharmaceutical-B (02171) announced that, according to the “Notice on the Adjustment of Hong Kong Stock Connect Targets under Shanghai-Hong Kong Stock Connect” published on March 6, 2026, and the “Announcement on the Adjustment of the List of Securities under Shenzhen-Hong Kong Stock Connect” also published on March 6, 2026, the company’s shares issued and listed on the Hong Kong Stock Exchange are now included in the list of eligible stocks for both Shanghai-Hong Kong and Shenzhen-Hong Kong Stock Connect (collectively referred to as “Stock Connect”). This adjustment takes effect from March 9, 2026.

This inclusion reflects the market’s recognition of the company’s core CAR-T business development potential, operational compliance, and share liquidity, aligning with the company’s long-term development strategy and the fundamental interests of all shareholders. After being included in Stock Connect, qualified mainland Chinese investors can directly buy and sell the company’s shares listed on the Hong Kong Stock Exchange through the Shanghai and Shenzhen Stock Exchange Stock Connect trading systems. This move is expected to provide mainland investors with a more convenient investment channel, significantly increase market attention and liquidity, and inject strong momentum into the company’s capital market development.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.